The present novel technology relates to an autologous or allogeneic mesenchymal stem cell (MSC) therapy that comprises a pre-determined amount of a processed bone marrow cellular matrix with a pre-determined amount of pre-mixture, where the pre-mixture includes quantities of anticoagulant solution, dextrose and phosphate buffered saline, and methods for production. The present novel technology further relates to methods of use of the therapy to treat various autoimmune diseases, alcohol related liver pathology, and acute soft tissue injuries, and the like, via intravenous infusion of the MSCs.
